Annual report pursuant to Section 13 and 15(d)

Restructuring

v3.3.1.900
Restructuring
12 Months Ended
Dec. 31, 2015
Restructuring Costs [Abstract]  
Restructuring
Restructuring
During the fourth quarter of 2013, the Board approved and committed to a restructuring plan to reduce the cost structure resulting from our decision to begin winding down our CodeXyme® cellulase enzymes program, which included a total of 15 employee terminations in the United States. For the year ended December 31, 2013, costs of $0.8 million of employee severance and other termination benefits have been recognized, consisting of $0.6 million in research and development expenses and $0.2 million in selling, general and administrative expenses. Associated with the restructuring Plan, we sold certain research and development assets that have become excess to future requirements (see Note 8 - Assets Held for Sale and Sale of Former Hungarian Subsidiary). All restructuring charges were fully paid out in 2014. We do not anticipate recording any further costs under this restructuring plan.